SCORE Search Results Details for Application 10552515 and Search Result 20080630_144055_us-10-552-515-6.rag.

This page gives you Search Results detail for the Application 10552515 and Search Result 20080630_144055_us-10-552-515-6.rag.

Go Back to previous page

GenCore version 6.2.1

OM protein - protein search, using sw model

Run on: June 30, 2008, 17:43:01 ; Search time 71 Seconds
(without alignments)
76.429 Million cell updates/sec

Title: US-10-552-515-6
Perfect score: 39
Sequence: 1 LLAIRLAFV 9

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters: 3405708

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200711:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000:*
4: geneseqp2001:*
5: geneseqp2002:*
6: geneseqp2003a:*
7: geneseqp2003b:*
8: geneseqp2004a:*

9: geneseqp2004b:*
10: geneseqp2005:*
11: geneseqp2006:*
12: geneseqp2007:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	39	100.0	9	8	ADT77669	Adt77669 Splice va
2	39	100.0	89	4	AAU22212	Aau22212 Human car
3	39	100.0	89	7	ADE46180	Ade46180 Human car
4	39	100.0	89	8	ADJ07598	Adj07598 Human car
5	39	100.0	139	5	AAE24066	Aae24066 Human pro
6	39	100.0	197	5	ABP41712	Abp41712 Human ova
7	39	100.0	312	6	ADI21193	Adi21193 Novel hum
8	39	100.0	483	7	ADM05305	Adm05305 Human pro
9	39	100.0	483	8	ADQ96290	Adq96290 T cell ac
10	39	100.0	483	10	AEC88235	Aec88235 Human cDN
11	39	100.0	608	8	ADQ96298	Adq96298 T cell ac
12	39	100.0	608	8	ADQ96286	Adq96286 T cell ac
13	39	100.0	782	6	ADX42387	Adx42387 Human col
14	39	100.0	782	7	ADT95905	Adt95905 Colon can
15	39	100.0	782	8	ADQ96288	Adq96288 T cell ac
16	39	100.0	782	8	ADQ96104	Adq96104 T cell ac
17	39	100.0	885	10	AEB13426	Aeb13426 Human pro
18	39	100.0	933	8	ADT77664	Adt77664 Splice va
19	39	100.0	933	11	AEL84788	Ael84788 Tumor mar
20	32	82.1	174	3	AAB56717	Aab56717 Human pro
21	32	82.1	233	6	ADA54456	Ada54456 Human pro
22	32	82.1	394	2	AAY00876	Aay00876 Human LAP
23	32	82.1	394	4	AAB93884	Aab93884 Human pro
24	32	82.1	394	4	AAM78909	Aam78909 Human pro
25	32	82.1	394	5	ABB90167	Abb90167 Human pol
26	32	82.1	394	12	AGI32617	Agi32617 Human pro
27	32	82.1	488	4	AAM42028	Aam42028 Human pol
28	32	82.1	536	4	AAM79893	Aam79893 Human pro
29	32	82.1	536	12	AGI34585	Agi34585 Human pro
30	31	79.5	164	7	ABO81636	Abo81636 Pseudomon
31	31	79.5	257	4	AAB87358	Aab87358 Human gen
32	31	79.5	257	5	ABG65362	Abg65362 Human alb
33	31	79.5	257	8	ADL78629	Adl78629 Albumin f
34	31	79.5	257	11	AEH08902	Aeh08902 Therapeut
35	31	79.5	257	12	AGI51730	Agi51730 Human The

36	31	79.5	594	4	AAB92637	Aab92637 Human pro
37	31	79.5	594	5	ABP43811	Abp43811 FLJ10261
38	31	79.5	594	8	ADJ75429	Adj75429 Marker ge
39	31	79.5	594	8	ADN04848	Adn04848 Antipsori
40	31	79.5	594	11	AEG11143	Aeg11143 Human FLJ
41	31	79.5	674	8	ADS28161	Ads28161 Bacterial
42	31	79.5	712	11	AEG11145	Aeg11145 Human tra
43	31	79.5	840	11	AEG11146	Aeg11146 Human tra
44	31	79.5	842	5	ABB92994	Abb92994 Herbicida
45	31	79.5	960	11	AEG11142	Aeg11142 Human tra

ALIGNMENTS

RESULT 1
ADT77669
ID ADT77669 standard; peptide; 9 AA.
XX
AC ADT77669;
XX
DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX
PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Bera TK, Lee B;
XX
DR WPI; 2004-758338/74.
XX
PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 6; 88pp; English.

```
XX
CC   The present sequence is that of a predicted epitope of human splice
CC   variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC   is predicted to bind HLA2-01 and was identified using an HLA binding
CC   motif program. It corresponds to amino acids 846-854 of SV-NGEP.
CC   Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC   acids of SV-NGEP which specifically bind to an antibody that specifically
CC   binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC   claimed. The invention provides methods for: detecting prostate cancer in
CC   a subject by contacting a sample with an antibody that specifically binds
CC   a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC   or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC   producing an immune response against a cell expressing SV-NGEP, for
CC   example in a subject with prostate cancer, by administering SV-NGEP
CC   polypeptide or polynucleotide to produce an immune response that
CC   decreases growth of the prostate cancer; inhibiting the growth of a
CC   malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC   lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC   these with the malignant cell; and inhibiting the growth of a malignant
CC   cell by contact with an antibody that specifically binds SV-NGEP, where
CC   the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ   Sequence 9 AA;

  Query Match             100.0%;  Score 39;  DB 8;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+06;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db          1 LLAIRLAFV 9


RESULT 2
AAU22212
ID   AAU22212 standard; protein; 89 AA.
XX
AC   AAU22212;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Human cardiovascular system antigen polypeptide SEQ ID No 986.
XX
KW   Cardiovascular system antigen; human; mouse; rabbit; goat; horse; cat;
KW   chicken; sheep; immunosuppressive; antiarthritic; vasotropic; dog;
KW   antirheumatic; antiproliferative; cytostatic; cardiant; neuroprotective;
KW   cerebroprotective; nootropic; antibacterial; virucide; fungicide; cancer;
KW   ophthalmological; vulnerary; gene therapy; autoimmune disease; neoplasm;
KW   hyperproliferative disorder; breast; liver; cardiovascular disorder;
```

KW cerebrovascular disorder; nervous system disorder; bacterial infection;
KW fungal infection; viral infection; ocular disorder; endocrine disorder;
KW gastrointestinal disorder; renal disorder; respiratory disorder;
KW wound healing; skin aging; organ transplantation; tissue regeneration;
KW anti-infertility.
XX
OS Homo sapiens.
XX
PN WO200155321-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001340.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.

PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.

PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.

PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451930/48.
DR N-PSDB; AAS35486.
XX
PT New cardiovascular system related polynucleotides and polypeptides,
PT useful for diagnosing, treating and/or preventing disorders of the
PT cardiovascular system.
XX
PS Claim 11; SEQ ID NO 986; 674pp; English.
XX
CC Sequences AAU21852-AAU22466 represent the cardiovascular system antigen
CC polypeptides of the invention. Cardiovascular system antigens and their
CC associated polynucleotides are useful in the diagnosis, treatment and
CC prevention of various types of disorders in e.g. humans, mice, rabbits,
CC goats, horses, cats, dogs, chickens or sheep. A pathological condition
CC can be determined by detecting the presence or absence of a mutation in a
CC cardiovascular system antigen polynucleotide. The treatable disorders
CC include autoimmune diseases such as rheumatoid arthritis,
CC hyperproliferative disorders such as neoplasms of the breast or liver,
CC cardiovascular disorders such as cardiac arrest, cerebrovascular
CC disorders such as cerebral ischaemia, nervous system disorders such as
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi,
CC ocular disorders such as corneal infection, endocrine disorders such as
CC premature labour and infertility, gastrointestinal disorders such as
CC Crohn's disease, renal disorders such as glomerulonephritis and
CC respiratory disorders such as asthma and pleurisy. The polypeptides can
CC also be used to aid wound healing, to prevent skin aging due to sunburn,
CC to maintain organs before transplantation, to regenerate tissues and in
CC chemotaxis. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX

Query Match 100.0%; Score 39; DB 4; Length 89;
Best Local Similarity 100.0%; Pred. No. 2;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LLAIRLAFV 9
|||||||||
Db 51 LLAIRLAFV 59

RESULT 3
ADE46180
ID ADE46180 standard; protein; 89 AA.
XX
AC ADE46180;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cardiovascular system related polypeptide #361.
XX
KW Human; cardiovascular system related polypeptide; cancer;
KW proliferative disorder; foetal abnormality; developmental abnormality;
KW haematopoietic disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW inflammation; allergy; neurological disorder; Alzheimer's disease;
KW Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW cardiovascular disorder; angiogenic disorder; kidney disorder;
KW gastrointestinal disorder; pregnancy-related disorder;
KW endocrine disorder.
XX
OS Homo sapiens.
XX
PN US2003059908-A1.
XX
PD 27-MAR-2003.
XX
PF 07-MAR-2002; 2002US-00091504.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.

PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.

PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.

PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764869.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2003-743766/70.
DR N-PSDB; ADE45565.
XX
PT New cardiovascular system related polynucleotides and polypeptides,
PT useful for preventing, treating, or ameliorating a medical condition,
PT such as cancer of cardiovascular tissues and cancer metastases.
XX
PS Claim 11; SEQ ID NO 986; 262pp; English.
XX
CC The invention relates to human cardiovascular system related polypeptides
CC and the polynucleotides encoding them. The polypeptides, polynucleotides
CC and antibodies to the polypeptides are useful for diagnosing a
CC pathological condition or a susceptibility to a pathological condition,
CC for preventing, treating, or ameliorating a medical condition, such as
CC cancer of cardiovascular system tissues, proliferative disorders, foetal
CC and developmental abnormalities, haematopoietic disorders, diseases of
CC the immune system, AIDS, autoimmune diseases (e.g., rheumatoid
CC arthritis), inflammation, allergies, neurological disorders (e.g.,
CC Alzheimer's disease, Parkinson's disease), cognitive disorders,
CC schizophrenia, asthma, skin disorders (e.g., psoriasis), sepsis,
CC diabetes, atherosclerosis, cardiovascular disorders, angiogenic
CC disorders, kidney disorders, gastrointestinal disorders, pregnancy-
CC related disorders, endocrine disorders and infections. The nucleic acids
CC are also useful for chromosome identification, radiation hybrid mapping
CC or long-range restriction mapping. The polypeptides and polynucleotides
CC may also be used as food additives or preservatives to increase or

```
CC   decrease storage capabilities, fat content or other nutritional
CC   components. This sequence represents a human cardiovascular system
CC   related polypeptide of the invention.
XX
SQ   Sequence 89 AA;

  Query Match             100.0%;  Score 39;  DB 7;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 2;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db         51 LLAIRLAFV 59


RESULT 4
ADJ07598
ID   ADJ07598 standard; protein; 89 AA.
XX
AC   ADJ07598;
XX
DT   04-NOV-2004  (first entry)
XX
DE   Human cardiovascular system associated polypeptide SeqID986.
XX
KW   autoimmune disease; rheumatoid arthritis; hyperproliferative disorder;
KW   breast neoplasms; liver neoplasm; cardiovascular disorder;
KW   cardiac arrest; cerebrovascular disorder; cerebral ischaemia;
KW   angiogenesis; nervous system disorder; Alzheimer's disease; infection;
KW   ocular disorder; corneal infection; wound healing;
KW   epithelial cell proliferation; skin aging; sunburn;
KW   organ transplantation; cell culture; tissue regeneration; chemotaxis;
KW   food additive; preservative; cardiovascular system associated antigen;
KW   nuclear factor kappaB; NFkappaB; promoter element; human.
XX
OS   Homo sapiens.
XX
PN   US2004005575-A1.
XX
PD   08-JAN-2004.
XX
PF   26-AUG-2002; 2002US-00227577.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
```

PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.

PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.

PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764869.
PR 07-MAR-2002; 2002US-00091504.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2004-081713/08.
DR N-PSDB; ADJ06983.
XX
PT New cardiovascular system-related nucleic acid molecule, useful for
PT diagnosing, preventing or treating diseases of the cardiovascular system,
PT and in chromosome mapping, drug screening or in pharmacogenomics.
XX
PS Claim 11; SEQ ID NO 986; 262pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule encoding a

```
CC   human cardiovascular system associated polypeptide (or antigens), or its
CC   fragment. Also included recombinant vectors, recombinant host cells, an
CC   isolated human cardiovascular system associated polypeptide (including
CC   its fragment, allelic variant, species homologue or epitope), an isolated
CC   antibody that binds specifically to a human cardiovascular system
CC   associated polypeptide, diagnosing a pathological condition or
CC   susceptibility to a pathological condition (comprising determining the
CC   presence or absence of a mutation in human cardiovascular system
CC   associated nucleic acid and diagnosing a condition based on the presence
CC   or absence of the mutation), identifying a binding partner to human
CC   cardiovascular system associated polypeptides, the gene corresponding to
CC   the human cardiovascular system associated cDNA sequence and identifying
CC   an activity in a biological assay comprising expressing the human
CC   cardiovascular system associated cDNA in a cell, isolating the
CC   supernatant, detecting an activity in a biological assay and identifying
CC   the protein in the supernatant having the activity. The human
CC   cardiovascular system associated nucleic acids and polypeptides are used
CC   to prevent, treat or ameliorate a medical condition (for example in
CC   humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep), for
CC   example autoimmune diseases such as rheumatoid arthritis,
CC   hyperproliferative disorders, for example neoplasms of the breast or

  Query Match             100.0%;  Score 39;  DB 8;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 2;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db         51 LLAIRLAFV 59


RESULT 5
AAE24066
ID   AAE24066 standard; protein; 139 AA.
XX
AC   AAE24066;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human prostate specific protein (PSP) #9.
XX
KW   Human; prostate specific protein; PSP; prostate specific nucleic acid;
KW   vaccine; transgenic; prostate cancer; gene therapy; transgenic animal;
KW   PSNA.
XX
OS   Homo sapiens.
XX
PN   WO200224718-A1.
XX
```

```
PD   28-MAR-2002.
XX
PF   19-SEP-2001; 2001WO-US029386.
XX
PR   19-SEP-2000; 2000US-0233746P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Sun Y,  Recipon H,  Cafferkey R,  Ali S;
XX
DR   WPI; 2002-471216/50.
XX
PT   Novel isolated prostate specific polypeptide useful for identifying,
PT   diagnosing, monitoring, staging, imaging, and treating prostate cancer
PT   and non-cancerous disease states in prostate.
XX
PS   Claim 37; Page 202-203; 210pp; English.
XX
CC   The invention relates to prostate specific proteins (PSP) and prostate
CC   specific nucleic acids (PSNA). Sequences of the invention are useful for
CC   identifying, diagnosing, monitoring, staging, imaging and treating
CC   prostate cancer and non-cancerous disease states in prostate. They are
CC   also useful for producing engineered prostate tissue for treatment and
CC   research. The PSNA sequences are used in gene therapy and for producing
CC   transgenic animals and cells. The invention is also used as vaccines. The
CC   present sequence is human prostate specific protein of the invention
XX
SQ   Sequence 139 AA;

  Query Match             100.0%;  Score 39;  DB 5;  Length 139;
  Best Local Similarity   100.0%;  Pred. No. 3.2;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        127 LLAIRLAFV 135


RESULT 6
ABP41712
ID   ABP41712 standard; protein; 197 AA.
XX
AC   ABP41712;
XX
DT   22-AUG-2002  (first entry)
XX
DE   Human ovarian antigen HLMHM83, SEQ ID NO:2844.
XX
KW   Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
```

KW ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW inflammatory condition; immune disorder; blood disorder;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disorder; urinary system disorder; drug screening;
KW gene therapy; chromosome mapping; forensic analysis;
KW antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW antiinflammatory; gynaecological; reproductive.
XX
OS Homo sapiens.
XX
PN WO200200677-A1.
XX
PD 03-JAN-2002.
XX
PF 07-JUN-2001; 2001WO-US018569.
XX
PR 07-JUN-2000; 2000US-0209467P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Birse CE, Rosen CA;
XX
DR WPI; 2002-147878/19.
DR N-PSDB; ABQ54789.
XX
PT Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian
PT cancer), immune disorders, cardiovascular disorders and neurological
PT diseases.
XX
PS Claim 11; SEQ ID NO 2844; 2922pp; English.
XX
CC The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC encompasses polypeptides 90% identical and polynucleotides 95% identical
CC to the sequences of the invention. The invention additionally relates to
CC recombinant vectors and host cells comprising human ovarian antigen
CC polynucleotides, antibodies against human ovarian antigens, and the use
CC of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC treating, prognosing or preventing various ovary and/or breast-related
CC disorders. Such conditions include ovarian cancer and breast cancer, and
CC metastatic tumours of ovarian or breast origin, reproductive system
CC disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC vaginitis), immune disorders (e.g., congenital and acquired

```
CC   immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC   blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC   respiratory disorders, neurological disorders, gastrointestinal disorders
CC   and urinary system disorders. Ovarian antigen polypeptides and
CC   polynucleotides may also be used in screening for compounds which
CC   modulate ovarian antigen expression or activity. The polynucleotides may
CC   further be used for gene therapy, chromosome mapping, in the
CC   identification of individuals and in forensic analysis, and the
CC   polypeptides may be used as food additives or to prepare antibodies
CC   useful in disease diagnosis, drug targeting and phenotyping. The present
CC   sequence represents a human ovarian antigen of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 197 AA;

  Query Match             100.0%;  Score 39;  DB 5;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        113 LLAIRLAFV 121


RESULT 7
ADI21193
ID   ADI21193 standard; protein; 312 AA.
XX
AC   ADI21193;
XX
DT   15-APR-2004  (first entry)
XX
DE   Novel human protein #168.
XX
KW   forensic; nutritional source; damaged tissue; diseased tissue;
KW   myeloid cell disorder; lymphoid cell disorder;
KW   bone cartilage tissue growth; tendon tissue growth;
KW   ligament tissue growth; nerve tissue growth; regeneration; wound healing;
KW   tissue repair; tissue replacement; burn; incision; ulcer; cancer; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025148-A2.
XX
PD   27-MAR-2003.
XX
PF   19-SEP-2002; 2002WO-US029964.
```

XX
PR 19-SEP-2001; 2001US-0323739P.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Asundi V, Goodrich RW, Ren F, Zhang J, Zhao QA, Wang J;
PI Ghosh M, Xue AJ, Wehrman T, Weng G, Zhou P, Drmanac RT, Wang D;
PI Haley-Vicente D;
XX
DR WPI; 2003-354603/33.
DR N-PSDB; ADI21909.
XX
PT New polynucleotides and secreted proteins, useful for treating myeloid or
PT lymphoid cell disorders, in bone cartilage, tendon, ligament and nerve
PT tissue growth or regeneration, in wound healing, and in tissue repair and
PT replacement.
XX
PS Claim 20; SEQ ID NO 444; 156pp; English.
XX
CC The invention relates to an isolated polynucleotide encoding a
CC polypeptide with biological activity. The polynucleotides and
CC polypeptides are useful in diagnostics, forensics, gene mapping,
CC identification of mutations responsible for genetic disorders and other
CC traits, to assess biodiversity, as nutritional sources or supplements.
CC The polynucleotides may also be used as molecular weight markers,
CC chromosome markers or map related gene positions, or as an antigen to
CC raise anti-DNA antibodies or elicit immune response. The polypeptides are
CC useful for raising antibodies, as markers for tissues in which the
CC corresponding polypeptide is expressed, for re-engineering damaged or
CC diseased tissues, for treating myeloid or lymphoid cell disorders, in
CC bone cartilage, tendon, ligament and/or nerve tissue growth or
CC regeneration, in wound healing, in tissue repair and replacement, in
CC healing of burns, incisions and ulcers, and in treating cancer. The
CC present sequence represents the amino acid sequence of a novel human
CC protein.
XX
SQ Sequence 312 AA;

Query Match 100.0%; Score 39; DB 6; Length 312;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 LLAIRLAFV 9
              |||||||||
Db        228 LLAIRLAFV 236
```

RESULT 8
ADM05305

```
ID   ADM05305 standard; protein; 483 AA.
XX
AC   ADM05305;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human protein of the invention SEQ ID NO:3990.
XX
KW   human; gene therapy; diagnostic marker; pharmaceutical.
XX
OS   Homo sapiens.
XX
PN   EP1347046-A1.
XX
PD   24-SEP-2003.
XX
PF   12-APR-2002; 2002EP-00008400.
XX
PR   22-MAR-2002; 2002JP-00137785.
XX
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI   Isogai T,  Sugiyama T,  Otsuki T,  Wakamatsu A,  Sato H,  Ishii S;
PI   Yamamoto J,  Isono Y,  Hio Y,  Otsuka K,  Nagai K,  Irie R,  Tamechika I;
PI   Seki N,  Yoshikawa T,  Otsuka M,  Nagahari K,  Masuho Y;
XX
DR   WPI; 2003-723558/69.
DR   N-PSDB; ADM02862.
XX
PT   New polynucleotides and polypeptides are useful in gene therapy, for
PT   developing a diagnostic marker or medicines for regulating their
PT   expression and activity, or as a target of gene therapy.
XX
PS   Claim 1; SEQ ID NO 3990; 305pp; English.
XX
CC   The invention relates to a novel human polynucleotide and the encoded
CC   polypeptide. A polynucleotide of the invention may have a use in gene
CC   therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
CC   as a primer for synthesizing the polynucleotide or as a probe for
CC   detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
CC   useful in gene therapy, for developing a diagnostic marker or medicines
CC   for regulating their expression and activity, or as a target of gene
CC   therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC   are useful as pharmaceutical agents. The present sequence represents a
CC   protein sequence of the invention.
XX
SQ   Sequence 483 AA;

  Query Match             100.0%;  Score 39;  DB 7;  Length 483;
```

```
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        399 LLAIRLAFV 407


RESULT 9
ADQ96290
ID   ADQ96290 standard; protein; 483 AA.
XX
AC   ADQ96290;
XX
DT   07-OCT-2004  (first entry)
XX
DE   T cell activation associated protein #234.
XX
KW   antiallergic; antiarthritic; antiasthmatic; antidiabetic; anti-HIV;
KW   antimicrobial; antirheumatic; immunosuppressive; neuroprotective;
KW   gene therapy; T cell activation; diagnosis; autoimmune disease;
KW   rheumatoid arthritis; asthma; multiple sclerosis; diabetes;
KW   allergic disease; infectious disease; AIDS; chronic rejection; organ;
KW   bone-marrow transplant.
XX
OS   Homo sapiens.
XX
PN   WO2004058805-A2.
XX
PD   15-JUL-2004.
XX
PF   25-DEC-2003; 2003WO-JP016715.
XX
PR   26-DEC-2002; 2002JP-00376365.
PR   27-DEC-2002; 2002US-0436473P.
PR   25-APR-2003; 2003JP-00122113.
PR   28-APR-2003; 2003US-0465792P.
PR   21-OCT-2003; 2003JP-00360559.
PR   22-OCT-2003; 2003US-0512846P.
XX
PA   (ASAH ) ASAHI KASEI PHARMA CORP.
XX
PI   Matsuda A,  Yoneta S;
XX
DR   WPI; 2004-593134/57.
DR   N-PSDB; ADQ96289.
XX
PT   New purified protein involved in T cell activation, useful for
PT   diagnosing, preventing and/or treating acquired immunodeficiency
```

```
PT   syndrome, autoimmune (e.g. rheumatoid arthritis, and diabetes), allergic
PT   and infectious diseases.
XX
PS   Claim 1; SEQ ID NO 468; 2828pp; English.
XX
CC   The invention relates to purified proteins and genes encoding them, that
CC   are involved in T cell activation (I) and has an amino acid deletion,
CC   substitution or addition in the amino acid sequences. The methods and
CC   compositions of the present invention are useful for the diagnosis,
CC   prevention and/or treatment of autoimmune disease (rheumatoid arthritis,
CC   asthma, multiple sclerosis and diabetes), allergic disease, infectious
CC   disease, AIDS, and acute or chronic rejection at organ transplant or bone
CC   -marrow transplant. This sequence corresponds to a protein involved in T
CC   cell activation.
XX
SQ   Sequence 483 AA;

  Query Match             100.0%;  Score 39;  DB 8;  Length 483;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        399 LLAIRLAFV 407


RESULT 10
AEC88235
ID   AEC88235 standard; protein; 483 AA.
XX
AC   AEC88235;
XX
DT   01-DEC-2005  (first entry)
XX
DE   Human cDNA clone protein SALGL10001710, SEQ ID 3990.
XX
KW   Osteopathic; Cytostatic; Antiinflammatory; Gastrointestinal-Gen.;
KW   Antiulcer; Gene Therapy; Osteoporosis; cancer; inflammation; gastritis;
KW   stomach ulcer; gastrointestinal ulcer.
XX
OS   Homo sapiens.
XX
PN   EP1580263-A1.
XX
PD   28-SEP-2005.
XX
PF   12-APR-2002; 2004EP-00027348.
XX
PR   22-MAR-2002; 2002JP-00137785.
```

```
PR   12-APR-2002; 2002EP-00008400.
XX
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI   Isogai T,  Sugiyama T,  Otsuki T,  Wakamatsu A,  Sato H,  Ishii S;
PI   Yamamoto J,  Isono Y,  Hio Y,  Otsuka K,  Nagai K,  Irie R,  Tamechika I;
PI   Seki N,  Yoshikawa T,  Otsuka M,  Nagahari K,  Masuho Y;
XX
DR   WPI; 2005-667421/69.
DR   N-PSDB; AEC85792.
XX
PT   New full-length cDNA sequences, useful for treating diseases, e.g.
PT   osteoporosis, cancer, inflammation, gastritis, or gastroduodenal ulcer.
XX
PS   Example 3; SEQ ID NO 3990; 296pp; English.
XX
CC   The present invention relates to novel human cDNAs (AEC84246-AEC86688)
CC   encoding proteins AEC86689-AEC89131. The cDNAs are useful for analyzing
CC   the functions of the proteins, and for developing medicines for diseases
CC   e.g. osteoporosis, cancer, inflammation, gastritis, or gastroduodenal
CC   ulcer. Note: The sequence data for this patent did not form part of the
CC   printed specification but was obtained in electronic format directly from
CC   EPO.
XX
SQ   Sequence 483 AA;

  Query Match             100.0%;  Score 39;  DB 10;  Length 483;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        399 LLAIRLAFV 407


RESULT 11
ADQ96298
ID   ADQ96298 standard; protein; 608 AA.
XX
AC   ADQ96298;
XX
DT   07-OCT-2004  (first entry)
XX
DE   T cell activation associated protein #238.
XX
KW   antiallergic; antiarthritic; antiasthmatic; antidiabetic; anti-HIV;
KW   antimicrobial; antirheumatic; immunosuppressive; neuroprotective;
KW   gene therapy; T cell activation; diagnosis; autoimmune disease;
KW   rheumatoid arthritis; asthma; multiple sclerosis; diabetes;
```

KW allergic disease; infectious disease; AIDS; chronic rejection; organ;
KW bone-marrow transplant.
XX
OS Homo sapiens.
XX
PN WO2004058805-A2.
XX
PD 15-JUL-2004.
XX
PF 25-DEC-2003; 2003WO-JP016715.
XX
PR 26-DEC-2002; 2002JP-00376365.
PR 27-DEC-2002; 2002US-0436473P.
PR 25-APR-2003; 2003JP-00122113.
PR 28-APR-2003; 2003US-0465792P.
PR 21-OCT-2003; 2003JP-00360559.
PR 22-OCT-2003; 2003US-0512846P.
XX
PA (ASAH) ASAHI KASEI PHARMA CORP.
XX
PI Matsuda A, Yoneta S;
XX
DR WPI; 2004-593134/57.
DR N-PSDB; ADQ96297.
XX
PT New purified protein involved in T cell activation, useful for
PT diagnosing, preventing and/or treating acquired immunodeficiency
PT syndrome, autoimmune (e.g. rheumatoid arthritis, and diabetes), allergic
PT and infectious diseases.
XX
PS Claim 1; SEQ ID NO 476; 2828pp; English.
XX
CC The invention relates to purified proteins and genes encoding them, that
CC are involved in T cell activation (I) and has an amino acid deletion,
CC substitution or addition in the amino acid sequences. The methods and
CC compositions of the present invention are useful for the diagnosis,
CC prevention and/or treatment of autoimmune disease (rheumatoid arthritis,
CC asthma, multiple sclerosis and diabetes), allergic disease, infectious
CC disease, AIDS, and acute or chronic rejection at organ transplant or bone
CC -marrow transplant. This sequence corresponds to a protein involved in T
CC cell activation.
XX
SQ Sequence 608 AA;

Query Match 100.0%; Score 39; DB 8; Length 608;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LLAIRLAFV 9

```
                 |||||||||
Db         524 LLAIRLAFV 532


RESULT 12
ADQ96286
ID   ADQ96286 standard; protein; 608 AA.
XX
AC   ADQ96286;
XX
DT   07-OCT-2004  (first entry)
XX
DE   T cell activation associated protein #232.
XX
KW   antiallergic; antiarthritic; antiasthmatic; antidiabetic; anti-HIV;
KW   antimicrobial; antirheumatic; immunosuppressive; neuroprotective;
KW   gene therapy; T cell activation; diagnosis; autoimmune disease;
KW   rheumatoid arthritis; asthma; multiple sclerosis; diabetes;
KW   allergic disease; infectious disease; AIDS; chronic rejection; organ;
KW   bone-marrow transplant.
XX
OS   Homo sapiens.
XX
PN   WO2004058805-A2.
XX
PD   15-JUL-2004.
XX
PF   25-DEC-2003; 2003WO-JP016715.
XX
PR   26-DEC-2002; 2002JP-00376365.
PR   27-DEC-2002; 2002US-0436473P.
PR   25-APR-2003; 2003JP-00122113.
PR   28-APR-2003; 2003US-0465792P.
PR   21-OCT-2003; 2003JP-00360559.
PR   22-OCT-2003; 2003US-0512846P.
XX
PA   (ASAH ) ASAHI KASEI PHARMA CORP.
XX
PI   Matsuda A,  Yoneta S;
XX
DR   WPI; 2004-593134/57.
DR   N-PSDB; ADQ96285.
XX
PT   New purified protein involved in T cell activation, useful for
PT   diagnosing, preventing and/or treating acquired immunodeficiency
PT   syndrome, autoimmune (e.g. rheumatoid arthritis, and diabetes), allergic
PT   and infectious diseases.
XX
PS   Claim 1; SEQ ID NO 464; 2828pp; English.
```

```
XX
CC   The invention relates to purified proteins and genes encoding them, that
CC   are involved in T cell activation (I) and has an amino acid deletion,
CC   substitution or addition in the amino acid sequences. The methods and
CC   compositions of the present invention are useful for the diagnosis,
CC   prevention and/or treatment of autoimmune disease (rheumatoid arthritis,
CC   asthma, multiple sclerosis and diabetes), allergic disease, infectious
CC   disease, AIDS, and acute or chronic rejection at organ transplant or bone
CC   -marrow transplant. This sequence corresponds to a protein involved in T
CC   cell activation.
XX
SQ   Sequence 608 AA;

  Query Match             100.0%;  Score 39;  DB 8;  Length 608;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        524 LLAIRLAFV 532


RESULT 13
ADX42387
ID   ADX42387 standard; protein; 782 AA.
XX
AC   ADX42387;
XX
DT   15-JUN-2007  (revised)
DT   21-APR-2005  (first entry)
XX
DE   Human colon cancer protein SEQ ID NO 1424.
XX
KW   Cytostatic; Immunostimulant; therapy; diagnosis; colon cancer; neoplasm;
KW   BOND_PC; transmembrane protein 16J;
KW   Transmembrane protein 16J [Homo sapiens]; GO16021.
XX
OS   Homo sapiens.
XX
PN   WO200274156-A2.
XX
PD   26-SEP-2002.
XX
PF   01-FEB-2002; 2002WO-US002870.
XX
PR   02-FEB-2001; 2001US-0267400P.
PR   07-FEB-2001; 2001US-0267382P.
PR   11-MAY-2001; 2001US-0290322P.
PR   12-JUL-2001; 2001US-0305265P.
```

PR 16-AUG-2001; 2001US-0313077P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Jiang Y, Chenault RA, Xu J, Indirias CY, Lodes MJ, Secrist H;
PI Carter D, Fanger GR, Smith CL, Durham M, Stolk JA;
XX
DR WPI; 2003-040540/03.
DR N-PSDB; ADX42384.
DR PC:NCBI; gi118763738.
XX
PT New isolated nucleic acids and polypeptides capable of eliciting a
PT humoral and/or cellular immune response, useful for diagnosing,
PT preventing or treating cancer, particularly colon cancer.
XX
PS Claim 2; SEQ ID NO 1424; 244pp; English.
XX
CC The invention relates to a new isolated nucleic acid. The nucleic acids,
CC polypeptides, antibodies are useful for diagnosing, preventing or
CC treating cancer, particularly colon cancer. The nucleic acid and
CC polypeptides are also useful in DNA strand invasion, antisense
CC inhibition, mutational analysis, nucleic acid purification, isolation of
CC transcriptionally active genes, blocking or transcription factor binding,
CC genome cleavage or in situ hybridization, and as enhancers of
CC transcription or biomarkers. The kits are useful for detecting antibody
CC binding. The present sequence represents a human colon cancer protein.
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 782 AA;

Query Match 100.0%; Score 39; DB 6; Length 782;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LLAIRLAFV 9
|||||||||
Db 698 LLAIRLAFV 706

RESULT 14
ADT95905
ID ADT95905 standard; protein; 782 AA.
XX
AC ADT95905;
XX
DT 15-JUN-2007 (revised)
DT 16-DEC-2004 (first entry)

XX
DE Colon cancer associated human C637S polypeptide.
XX
KW Colon cancer; T cell; tumour protein; C634S; C635S; C637S; C640S; C636S;
KW humoral immune response; cellular immune response; cytostatic;
KW immunostimulant; human; BOND_PC; transmembrane protein 16J;
KW Transmembrane protein 16J [Homo sapiens]; GO16021.
XX
OS Homo sapiens.
XX
PN US2003087818-A1.
XX
PD 08-MAY-2003.
XX
PF 01-FEB-2002; 2002US-00066543.
XX
PR 02-FEB-2001; 2001US-0267400P.
PR 07-FEB-2001; 2001US-0267382P.
PR 11-MAY-2001; 2001US-0290322P.
PR 12-JUL-2001; 2001US-0305265P.
PR 16-AUG-2001; 2001US-0313077P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Jiang Y, Chenault RA, Xu J, Indirias CY, Lodes MJ, Secrist H;
PI Carter D, Fanger GR, Smith CL, Durham M, Stolk JA;
XX
DR WPI; 2003-040540/03.
DR N-PSDB; ADT95902.
DR PC:NCBI; gi118763738.
XX
PT New isolated nucleic acids and polypeptides capable of eliciting a
PT humoral and/or cellular immune response, useful for diagnosing,
PT preventing or treating cancer, particularly colon cancer.
XX
PS Claim 2; SEQ ID NO 1424; 87pp; English.
XX
CC The invention relates to polynucleotide and polypeptide sequences
CC associated with cancer, particularly colon cancer. Also disclosed are (i)
CC an expression vector comprising the polynucleotide, (ii) a host cell
CC transformed or transfected with the expression vector, (iii) an isolated
CC antibody, or its antigen-binding fragment, which specifically binds to
CC the polypeptide, (iv) a method of detecting or determining the presence
CC of cancer in a patient, (v) a fusion protein comprising at least one of
CC the polypeptides, (vi) an oligonucleotide that hybridises to the
CC polynucleotide sequence under highly stringent conditions, and (vii) a
CC method of stimulating and/or expanding T cells specific for a tumour
CC protein. The polypeptide specifically comprises the amino acid sequence
CC of C634S, C635S, C637S, C640S, C636S or one of the potential open reading

```
CC   frames (ORFs) of C636S. These polypeptides are encoded by the
CC   polynucleotide sequences, where both are capable of eliciting a humoral
CC   and/or cellular immune response. The polynucleotides, polypeptides, and
CC   antibodies are useful for diagnosing, preventing or treating cancer,
CC   particularly colon cancer. The polynucleotide and polypeptide sequences
CC   are also useful in DNA strand invasion, antisense inhibition, mutational
CC   analysis, nucleic acid purification, isolation of transcriptionally
CC   active genes, blocking or transcription factor binding, genome cleavage
CC   or in situ hybridisation, and as enhancers of transcription or
CC   biomarkers. This sequence represents a human colon cancer associated
CC   polypeptide. Note: The sequence data for this patent was obtained in
CC   electronic format directly from the USPTO web site at seqdata.uspto.gov
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 782 AA;

  Query Match             100.0%;  Score 39;  DB 7;  Length 782;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LLAIRLAFV 9
              |||||||||
Db        698 LLAIRLAFV 706


RESULT 15
ADQ96288
ID   ADQ96288 standard; protein; 782 AA.
XX
AC   ADQ96288;
XX
DT   15-JUN-2007  (revised)
DT   07-OCT-2004  (first entry)
XX
DE   T cell activation associated protein #233.
XX
KW   antiallergic; antiarthritic; antiasthmatic; antidiabetic; anti-HIV;
KW   antimicrobial; antirheumatic; immunosuppressive; neuroprotective;
KW   gene therapy; T cell activation; diagnosis; autoimmune disease;
KW   rheumatoid arthritis; asthma; multiple sclerosis; diabetes;
KW   allergic disease; infectious disease; AIDS; chronic rejection; organ;
KW   bone-marrow transplant; BOND_PC; transmembrane protein 16J;
KW   Transmembrane protein 16J [Homo sapiens]; GO16021.
XX
OS   Homo sapiens.
XX
PN   WO2004058805-A2.
```

XX
PD 15-JUL-2004.
XX
PF 25-DEC-2003; 2003WO-JP016715.
XX
PR 26-DEC-2002; 2002JP-00376365.
PR 27-DEC-2002; 2002US-0436473P.
PR 25-APR-2003; 2003JP-00122113.
PR 28-APR-2003; 2003US-0465792P.
PR 21-OCT-2003; 2003JP-00360559.
PR 22-OCT-2003; 2003US-0512846P.
XX
PA (ASAH) ASAHI KASEI PHARMA CORP.
XX
PI Matsuda A, Yoneta S;
XX
DR WPI; 2004-593134/57.
DR N-PSDB; ADQ96287.
DR PC:NCBI; gi118763738.
XX
PT New purified protein involved in T cell activation, useful for
PT diagnosing, preventing and/or treating acquired immunodeficiency
PT syndrome, autoimmune (e.g. rheumatoid arthritis, and diabetes), allergic
PT and infectious diseases.
XX
PS Claim 1; SEQ ID NO 466; 2828pp; English.
XX
CC The invention relates to purified proteins and genes encoding them, that
CC are involved in T cell activation (I) and has an amino acid deletion,
CC substitution or addition in the amino acid sequences. The methods and
CC compositions of the present invention are useful for the diagnosis,
CC prevention and/or treatment of autoimmune disease (rheumatoid arthritis,
CC asthma, multiple sclerosis and diabetes), allergic disease, infectious
CC disease, AIDS, and acute or chronic rejection at organ transplant or bone
CC -marrow transplant. This sequence corresponds to a protein involved in T
CC cell activation.
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 782 AA;

Query Match 100.0%; Score 39; DB 8; Length 782;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LLAIRLAFV 9
|||||||||
Db 698 LLAIRLAFV 706

Search completed: June 30, 2008, 17:53:14
Job time : 73.875 secs

SCORE 1.0